REINSTATE YOUR SUBSCRIPTION AND SAVE $400

For over 25 years, Generic Line has been the leading resource of accurate, up-to-date news and analysis on FDA policies affecting generic drugs and drug patents.

Each bi-weekly issue keeps you and your firm up to date on crucial regulatory, legislative and business changes, including the latest on:

  • The establishment of a biosimilars approval pathway
  • What Strategies are most successful in challenging blockbuster brands
  • The FTC's growing efforts to stop pay-for-delay agreements.

Plus in every issue you get links to key documents, such as FDA guidances, warning letters, rules, full texts of proposed legislation and more. 


Biweekly, 24 issues/year, Electronic delivery.

 
 

$1,097 $697

 

Bonus

Renew Generic Line today and receive a FREE copy of our management report, Expediting the FDA Generic Drug Approval Process – a $397 Value! Plus receive a FREE copy of our webinar CD, Impact of GDUFA Performance Metrics on ANDA Risks and Practical Considerations — a $287 Value!

Key Benefits

LINKS TO KEY DOCUMENTS — Each issue provides you with links that support GEN's articles such as FDA guidances, warning letters, rules, full texts of proposed legislation and more.

FDANEWS DRUG DAILY BULLETIN — This daily email brings you important FDA and international regulatory, legislative and business news in the pharmaceutical industry.

ONLINE ACCESS — Consider our newsletter archive your personal library! Search your current issue — and hundreds of past issues — by keyword and relevancy.